guest ::
| Home > Publications database > TERT Promoter Mutations and Risk of Recurrence in Meningioma. > print |
| Home > Publications database > TERT Promoter Mutations and Risk of Recurrence in Meningioma. > print |
| 001 | 130464 | ||
| 005 | 20240228143435.0 | ||
| 024 | 7 | _ | |a 10.1093/jnci/djv377 |2 doi |
| 024 | 7 | _ | |a pmid:26668184 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4849806 |2 pmc |
| 024 | 7 | _ | |a 0027-8874 |2 ISSN |
| 024 | 7 | _ | |a 0198-0157 |2 ISSN |
| 024 | 7 | _ | |a 1460-2105 |2 ISSN |
| 024 | 7 | _ | |a altmetric:4877244 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05543 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sahm, Felix |0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a TERT Promoter Mutations and Risk of Recurrence in Meningioma. |
| 260 | _ | _ | |a Oxford |c 2016 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524813479_4217 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 650 | _ | 7 | |a TERT protein, human |0 EC 2.7.7.49 |2 NLM Chemicals |
| 650 | _ | 7 | |a Telomerase |0 EC 2.7.7.49 |2 NLM Chemicals |
| 700 | 1 | _ | |a Schrimpf, Daniel |0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc |b 1 |u dkfz |
| 700 | 1 | _ | |a Olar, Adriana |b 2 |
| 700 | 1 | _ | |a Koelsche, Christian |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Reuss, David |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Bissel, Juliane |b 5 |
| 700 | 1 | _ | |a Kratz, Annekathrin |b 6 |
| 700 | 1 | _ | |a Capper, David |b 7 |
| 700 | 1 | _ | |a Schefzyk, Sebastian |b 8 |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 9 |u dkfz |
| 700 | 1 | _ | |a Wang, Qianghu |b 10 |
| 700 | 1 | _ | |a Sulman, Erik P |b 11 |
| 700 | 1 | _ | |a Adeberg, Sebastian |b 12 |
| 700 | 1 | _ | |a Koch, Arend |b 13 |
| 700 | 1 | _ | |a Okuducu, Ali Fuat |b 14 |
| 700 | 1 | _ | |a Brehmer, Stefanie |b 15 |
| 700 | 1 | _ | |a Schittenhelm, Jens |b 16 |
| 700 | 1 | _ | |a Becker, Albert |b 17 |
| 700 | 1 | _ | |a Brokinkel, Benjamin |b 18 |
| 700 | 1 | _ | |a Schmidt, Melissa |b 19 |
| 700 | 1 | _ | |a Ull, Theresa |b 20 |
| 700 | 1 | _ | |a Gousias, Konstantinos |b 21 |
| 700 | 1 | _ | |a Kessler, Almuth Friederike |b 22 |
| 700 | 1 | _ | |a Lamszus, Katrin |b 23 |
| 700 | 1 | _ | |a Debus, Jürgen |b 24 |
| 700 | 1 | _ | |a Mawrin, Christian |b 25 |
| 700 | 1 | _ | |a Kim, Yoo-Jin |b 26 |
| 700 | 1 | _ | |a Simon, Matthias |b 27 |
| 700 | 1 | _ | |a Ketter, Ralf |b 28 |
| 700 | 1 | _ | |a Paulus, Werner |b 29 |
| 700 | 1 | _ | |a Aldape, Kenneth D |b 30 |
| 700 | 1 | _ | |a Herold-Mende, Christel |b 31 |
| 700 | 1 | _ | |a von Deimling, Andreas |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 32 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1093/jnci/djv377 |g Vol. 108, no. 5, p. djv377 - |0 PERI:(DE-600)1465951-7 |n 5 |p djv377 - |t Journal of the National Cancer Institute |v 108 |y 2016 |x 1460-2105 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130464 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 32 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a Allianz-Lizenz / DFG |0 StatID:(DE-HGF)0400 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JNCI-J NATL CANCER I : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b JNCI-J NATL CANCER I : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)G380-20160331 |k G380 |l KKE Neuropathologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G380-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|